Community Vulnerability: Measuring the Health Situation of a Population After COVID-19 Through Electronic Health Record Indicators

Healthcare, Journal Year: 2025, Volume and Issue: 13(1), P. 68 - 68

Published: Jan. 2, 2025

Background: The COVID-19 pandemic made people face the fact that we are all vulnerable. This vulnerability can be measured through Basic Variables of Care (BVC) using Vulnerability Index (CVI). Health systems work with indicators nurses consult to understand care and health situation their population. These provide valuable information on Objective: determine level community a population group from computerized clinical records Primary Care. Methods: observational, retrospective study March 2023 January 2024, sample 2106 assigned nurse at Meco Centre (Madrid, Spain). Phases: selection dashboard indicators, linkage BVC, score assignment, adjustment calculation CVI. Results: selects 18 out 376 included in Specific Dashboard; each indicator is related 6 10 BCVs, different rank values. Each adjusted by Correction Factor according number indicator. Finally, population-adjusted CVI scores 1.95 points (percentile 37.90). Conclusions: an essential tool diagnostics reflect given time, including changes crises such as pandemic.

Language: Английский

---

ОСОБЛИВОСТІ ПЕРЕБІГУ COVID-19 У ГОСПІТАЛІЗОВАНИХ ПАЦІЄНТІВ ЗАЛЕЖНО ВІД ТИПУ ОТРИМАНОЇ ВАКЦИНИ ТА КУРСУ ЩЕПЛЕНЬ

Інфекційні хвороби, Journal Year: 2025, Volume and Issue: 1, P. 27 - 31

Published: March 6, 2025

Згідно з літературними даними, вакцинація є дієвим методом запобігання тяжкому перебігу коронавірусної хвороби 2019, госпіталізації та смерті від неї. Дослідження ефективності дозволених до використання вакцин має важливе значення для формування стратегій громадського здоров’я захисту населення CОVID-19. Мета – проаналізувати можливий вплив особливостей вакцинації, а саме типу отриманих пройденого курсу щеплення, на ступінь тяжкості CОVID-19 у госпіталізованих вакцинованих пацієнтів, які захворіли вперше. Пацієнти і методи. включало 129 пацієнтів лабораторно підтвердженим інфікуванням SARS-CoV-2. За ступенем недуги хворі поділялись дві групи: середній тяжкий. типом отриманої вакцини також було виділено пацієнти, отримали мРНК-вакцини (Pfizer/Moderna), ті, інактивовану вакцину (CoronaVac). Також усіх поділено тих, хто отримав повний (2 дози) або частковий (1 доза) курс вакцинації. Результати. Більшість осіб мала (p=0,0001). У структурі всіх незалежно ступеня тяжкості, суттєво переважала група щеплення інактивованою вакциною CoronaVac (р=0,0004).

---

sTREM-1 as a Predictive Biomarker for Disease Severity and Prognosis in COVID-19 Patients

Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 3879 - 3891

Published: June 1, 2024

Background: Research on biomarkers associated with the severity and adverse prognosis of COVID-19 can be beneficial for improving patient outcomes. However, there is limited research role soluble TREM-1 (sTREM-1) in predicting patients. Methods: A total 115 patients admitted to emergency department Beijing Youan Hospital from February May 2023 were included study. Demographic information, laboratory measurements, blood samples sTREM-1 levels collected upon admission. Results: Our study found that plasma increased disease (moderate vs mild, p=0.0013; severe moderate, p=0.0195). had good predictive value 28-day mortality (area under ROC curve was 0.762 0.805, respectively). also exhibited significant correlations age, body temperature, respiratory rate, PaO 2 /FiO , PCT, CRP, CAR. Ultimately, through multivariate logistic regression analysis, we determined (OR 1.008, 95% CI: 1.002– 1.013, p=0.005), HGB 0.966, 0.935– 0.998, p=0.036), D-dimer 1.001, 1.000– p=0.009), CAR 1.761, 1.154– 2.688, p=0.009) independent predictors The combination these four markers yielded a strong cases an AUC 0.919 (95% 0.857 − 0.981). Conclusion: demonstrated mortality, serving as prognostic factor In future, anticipate conducting large-scale multicenter studies validate our findings. Keywords: COVID-19, sTREM-1, inflammation-related markers, severity,

Language: Английский

---

The potential role of perceived neighborhood social cohesion on COVID-19 vaccination uptake among individuals aged 50 and older: Results from the Korean Community Health Survey

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(10), P. e0312309 - e0312309

Published: Oct. 22, 2024

The COVID-19 pandemic highlighted the critical importance of vaccination in controlling infectious diseases. While previous research has identified social cohesion as a potential facilitator health behaviors, empirical studies exploring its direct impact on rates, especially across different age groups, remain limited. This cross-sectional study utilized data from 2021 Korean Community Health Survey, nationally representative survey conducted South Korea. analysis focused adults aged 50 and older, categorizing them into two groups (50–64 ≥65). We investigated association between perceived neighborhood status, for socio-economic concerns related to COVID-19. Statistical was using complex sample multiple logistic regression adjust confounders. included 135,352 participants, with an showing that group ≥65, higher levels were significantly associated increased uptake (aOR trust neighbors: 1.200, 95% CI: 1.058–1.362; aOR mutual assistance among 1.491, 1.312–1.695). Interestingly, these associations not significant 50–64 group. Additionally, satisfaction healthcare services both (aOR: 1.106, 1.004–1.219 50–64; aOR: 1.306, 1.160–1.471 Our findings suggest plays crucial role influencing older adults, particularly those 65 above. These results indicate policies aimed at enhancing may effectively improve elderly. Future should explore other assess causal relationships longitudinal studies.

Language: Английский

---

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 19, 2024

Abstract Background Global COVID-19 vaccination adapts to protect populations from emerging variants. This communication presents interim findings the new Omicron XBB adapted PHH-1V81 vaccine compared a mRNA against and JN.1 SARS-CoV-2 strains. Methods In Phase IIb/III pivotal trial, adults previously vaccinated with primary scheme at least one booster dose of an EU-approved randomly received either or BNT162b2 XBB.1.5 as single dose. The efficacy endpoint assessed neutralisation titers XBB.1.16 variant day 14. Secondary endpoints evaluated neutralization cellular immunity different Safety comprised solicited reactions up 7 post-vaccination serious adverse events until cut-off date analysis. Changes in humoral responses were reported GMT GMFR by PBNA VNA. Results At date, immunogenicity assessments included 599 participants. Both boosters elicited neutralizing antibodies XBB.1.5, inducing higher response for all PHH-1V8 triggers superior XBBs variants vaccine. Subgroup analysis consistently revealed antibody across age groups, number prior shots, infection history. involved 607 participants 14 visit, revealing favourable safety profiles without any vaccine-related (12 th December 2023). Conclusions demonstrates superiority on agains non-inferiority profile lower reactogenicity, confirming its potential candidate.

Language: Английский

---

Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4+ T-Cell Lymphopenia but Preserved Responses to CMV

Vaccines, Journal Year: 2024, Volume and Issue: 12(4), P. 386 - 386

Published: April 6, 2024

Immunogenicity of SARS-CoV-2 mRNA vaccines is highly heterogeneous in patients with inborn errors immunity (IEIs). This case report analyzes the immune response to COVID-19 two-dose primary vaccination followed by three boosters an IEI patient marked CD4+ T-cell cytopenia and diminished thymic output, comparison that raised against latent, chronic cytomegalovirus (CMV) infection. Serum IgG antibodies anti-spike (S) protein anti-CMV were both determined chemiluminescent microparticle immunoassays (CMIAs). CMV memory responses simultaneously evaluated vitro using activation-induced marker (AIM) assay via multicolor flow cytometry. Throughout 2-year follow-up included administration five doses vaccines, cellular anti-SARS-CoV-2-specific remained consistently negative, extremely weak humoral responses, while showed persistent reactivity peptides high-IgG CMV-specific titers. The assessment prevalent viruses essential order take adequate preventive measures.

Language: Английский

---

Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results

Vaccines, Journal Year: 2024, Volume and Issue: 12(8), P. 840 - 840

Published: July 25, 2024

(1) Background: The global coronavirus disease 2019 vaccination adapts to protect populations from emerging variants. This communication presents interim findings the new Omicron XBB.1.16-adapted PHH-1V81 protein-based vaccine compared an XBB.1.5-adapted mRNA against various acute respiratory syndrome 2 (SARS-CoV-2) strains. (2) Methods: In a Phase IIb/III pivotal trial, adults previously vaccinated with primary scheme and at least one booster dose of EU-approved randomly received either or BNT162b2 XBB.1.5 as single dose. efficacy endpoint assessed neutralization titers XBB.1.16 variant day 14. Secondary endpoints evaluated cellular immunity different Safety comprised solicited reactions up 7 post-vaccination serious adverse events until cut-off date analysis. Changes in humoral responses were by pseudovirion-based virus assays. (3) Results: At date, immunogenicity assessments included 599 participants. Both boosters elicited neutralizing antibodies XBB.1.16, XBB.1.5, JN.1, inducing higher response for all PHH-1V8 triggers superior antibody XBB variants vaccine. A subgroup analysis consistently revealed across age groups, SARS-CoV-2 infection history, number prior shots. safety (n = 607) 14 visit favorable profiles without any vaccine-related events. (4) Conclusions: demonstrates superiority on non-inferiority JN.1 profile lower reactogenicity, confirming its potential candidate.

Language: Английский

---

Investigating Non-Compliance with COVID-19 Vaccination through Hesitancy, Refusal, and Access Limitation: A Community-Based Survey from the Democratic Republic of the Congo

Journal of Biosciences and Medicines, Journal Year: 2024, Volume and Issue: 12(09), P. 280 - 306

Published: Jan. 1, 2024

Language: Английский

---

Analysis of the impact of coronavirus infection on human health: epidemiological data, vaccination strategies, psychological aspect, consequences (literature review)

Medicine Today and Tomorrow, Journal Year: 2024, Volume and Issue: 93(3)

Published: Sept. 30, 2024

The COVID-19 (COronaVIrus Disease 2019) pandemic has caused widespread morbidity, mortality, and socioeconomic crisis around the world. Since its first outbreak in 2019, evolved continuously, leading to emergence of several variants that have gained greater transmission efficiency, severity, immune evasion properties. Vaccination proven be an important strategy control spread virus mitigate impact. development multiple vaccines within 1 year virus's was unprecedented. purpose article analyze summarize scientific literature on impact global health, including epidemiological data, vaccination strategies, psychological pandemic, human health outcomes. analysis found been very effective reducing hospitalizations intensive care unit admissions. However, ongoing surveillance, monitoring options adaptive strategies are crucial maximize benefits effectively virus. Globally, dramatic rapid triggered social changes led increased burden mental fear-related behaviors. physical distancing imposed many parts world had a significant how general population communicates interacts with each other. Extreme avoidance lack contact created sense "disconnection" further exacerbated by inability meet friends family at gatherings supportive places such as churches, restaurants, workplaces, sports facilities. closure schools businesses, along rising unemployment, feelings isolation, financial hardship, anxiety, depression. provides information patients, namely, contributes distress, depression, suicide risk, post-traumatic stress disorder, cognitive impairment sleep disorders. Keywords: COVID, spread, vaccines,

Language: Английский

---

What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era?

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1180 - 1180

Published: Oct. 17, 2024

COVID-19 vaccines have reduced the negative health and economic impact of pandemic by preventing severe disease, hospitalizations deaths. In new socio-economic normality, vaccination strategy can be universal or high-risk seasonal not seasonal, different used. The achieve greater herd immunity effects is associated with costs than strategy. each country, optimal must decided considering advantages disadvantages assessing costs, cost-effectiveness strategies. should implemented when objective program to greatest benefits from its incremental ratio lower EUR 30,000-50,000 per QALY LYG. use adapted targeting currently circulating variants SARS-CoV-2 necessary avoid immune escape emerging variants.

Language: Английский

---